Pretreatment radiomic biomarker for immunotherapy responder prediction in stage IB–IV NSCLC (LCDigital-IO Study): a multicenter retrospective study by Bin Xu, Lan Liu, Shaowei Wu, Guangyi Wang, Guibin Qiao, Weijie Zhan, Daipeng Xie, Lintong Yao, Henian Yao, Guoqing Liao, Luyu Huang, Yubo Zhou, Peimeng You, Zekai Huang, Qiaxuan Li, Siyun Wang, Dong-Kun Zhang, Lawrence Wing-Chi Chan, Michael Lanuti, Haiyu Zhou

Get full text

High SHP2 expression determines the efficacy of PD‐1/PD‐L1 inhibitors in advanced KRAS mutant non‐small cell lung cancer by Hui‐Bo Feng, Yu Chen, Zhi Xie, Jie Jiang, Yu‐Min Zhong, Wei‐Bang Guo, Wen‐Qing Yan, Zhi‐Yi Lv, Dan‐Xia Lu, Hong‐Ling Liang, Fang‐Ping Xu, Jin‐Ji Yang, Xue‐Ning Yang, Qing Zhou, Dong‐Kun Zhang, Zhou Zhang, Shao‐Kun Chuai, Heng‐Hui Zhang, Yi‐Long Wu, Xu‐Chao Zhang

Get full text

PD-1/PD-L1 combined with LAG3 is associated with clinical activity of immune checkpoint inhibitors in metastatic primary pulmonary lymphoepithelioma-like carcinoma by Yu-Min Zhong, Yu-Min Zhong, Yu-Min Zhong, Kai Yin, Kai Yin, Yu Chen, Yu Chen, Zhi Xie, Zhi Xie, Zhi-Yi Lv, Zhi-Yi Lv, Jin-Ji Yang, Xue-Ning Yang, Qing Zhou, Bin-Chao Wang, Wen-Zhao Zhong, Ling-Ling Gao, Ling-Ling Gao, Wen-Bin Zhou, Ji Chen, Ji Chen, Hai-Yan Tu, Ri-Qiang Liao, Dong-Kun Zhang, Shui-Lian Zhang, Shui-Lian Zhang, Dan-Xia Lu, Dan-Xia Lu, Hong-Bo Zheng, Heng-Hui Zhang, Yi-Long Wu, Xu-Chao Zhang, Xu-Chao Zhang, Xu-Chao Zhang, Xu-Chao Zhang

Get full text